IGC Pharma, Inc. (IGC) Investor Relations Documents

IGC Pharma, Inc. (IGC) investor relations documents from the company's IR site: 1 presentation, 8 press releases; latest deck 2023-02-13. Read in-app with summaries. First-party data.

Radius Research – Webinar and Deep Dive with CEO Ram Mukunda & CFO Claudia Grimaldi: A Radius Research webinar featuring IGC Pharma CEO Ram Mukunda and CFO Claudia Grimaldi, held on February 13, 2023.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17Press releaseIGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
2026-08-11Press releaseIGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topl
2026-07-29Press releaseIGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campa
2026-07-09Press releaseIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonizati
2026-07-07Press releaseIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Compan
2026-06-02Press releaseIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
2026-04-14Press releaseIGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data R
2026-01-12Press releaseIGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site,
2023-02-13Investor meetingRadius Research – Webinar and Deep Dive with CEO Ram Mukunda & CFO Claudia Grimaldi

IGC overview · IGC earnings · IGC financials · IGC KPIs · IGC ownership · IGC peers · IGC filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.